CA-ELEGEN
24.1.2024 14:01:35 CET | Business Wire | Press release
Elegen, a leader in DNA manufacturing innovation, today announced a collaboration and licensing agreement with GSK (LSE/NYSE: GSK) to enable its use of Elegen’s proprietary cell-free DNA manufacturing technology in the development of GSK’s vaccines and medicines.
The terms of the agreement include upfront fees and purchase commitments of Elegen’s ENFINIA DNA to support GSK’s development of medicines and vaccines, including RNA vaccines. Elegen is also eligible to receive both near-term milestone payments relating to the development of new product features and a potential equity investment in Elegen by GSK.
Commercially launched in March of last year, ENFINIA DNA delivers NGS-verified, high-complexity, clonal-quality, linear DNA up to 7kb in as fast as seven business days. Unlike conventional synthesis of mRNA from linearized plasmid DNA, Elegen’s DNA is produced entirely cell-free, with the potential to enable a seamless transition from discovery to clinical scale-up under GMP. This technology may save significant time and substantial resources spent iteratively cloning, linearizing and purifying plasmid DNA as well as generating master cell banks. Elegen’s innovation in cell-free DNA manufacturing technology represents a significant leap forward that could power the next generation of mRNA, cell and gene therapies.
This collaboration follows the Early Access Program launched by Elegen in May of last year that offered DNA of longer length and higher complexity to select customers. “Over the past year dozens of customers, including multiple top 10 biopharma, have validated the unprecedented speed, length, accuracy and complexity of our cell-free DNA manufacturing technology,” said Matthew Hill, Ph.D., Elegen founder and CEO. “GSK recognizes the importance of a reliable, turnkey supply of DNA for a variety of applications for which speed, accuracy and quality of DNA synthesis are essential. This collaboration will expand our offering to include the clinical production of genetic medicines potentially including mRNA, cell and viral gene therapies.”
About Elegen
Elegen is bringing unique insights and technical innovation to create high-quality synthetic DNA faster, catalyzing the next revolution in the life sciences. The company is led by seasoned leaders with decades of experience developing novel and scalable approaches in molecular biology, chemistry and microfluidics. Elegen uses a proprietary microfluidics approach to build longer, higher-quality DNA on a faster timeline for agricultural, chemical, healthcare and pharma industries. Founded in 2017, Elegen is privately held and based in the San Francisco Bay Area. For more information, visit elegenbio.com and connect with us on LinkedIn and X (Twitter).
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240124105579/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2026 World Cup Triggers Corporate Travel Boom in Canada and U.S.3.6.2026 15:00:00 CEST | Press release
Navan data reveals Canadian business bookings have tripled, while U.S. hotel prices spike 30% as global enterprises lock in client entertainment Navan (NASDAQ: NAVN), the global AI-powered business travel and expense management platform, today released year-over-year data revealing global enterprises are leaning in heavily to the upcoming 2026 World Cup, with hotel and flight bookings for business travel to World Cup host cities up 46% to the U.S. and a massive 295% to Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602020779/en/ Navan data reveals Canadian business bookings have tripled, while U.S. hotel prices spike 30% as global enterprises lock in client entertainment “While headlines right now are focusing on softer-than-expected tourism demand and lagging leisure hotel bookings, our corporate data tells a different story,” said Dane Molter, SVP, Navan Group Travel Marketplace. “Companies are embracing the Wor
Onimusha: Way of the Sword Set to Release on September 25, 2026!3.6.2026 15:00:00 CEST | Press release
– A playable demo will be released ahead of the game’s launch – Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha: Way of the Sword, the latest title in the Onimusha series, is scheduled for release on September 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260603903549/en/ Onimusha: Way of the Sword key art Onimusha: Way of the Sword, which marks the first new title in the series in over 20 years, is a Japanese-inspired dark fantasy game that features Miyamoto Musashi as the protagonist and is set in an Edo-era Kyoto that has been twisted by malevolent clouds of Malice. Capcom is developing the title with the aim of appealing to a wide range of players through its exhilarating sword-based action and highly-unique characters. Ahead of launch, the company released a playable demo today*, June 3, 2026, titled Onimusha: Way of the Sword DEMO, to give players an opportunity to enjoy the appeal of the game as
Private Markets Firms Face SPV Execution Pressure as LP Demands Rise3.6.2026 14:30:00 CEST | Press release
86% of private markets professionals report rising LP requests for tailored SPV arrangementsTransparency and reporting rank as the top LP priority, cited by 76% of respondents82% report increased demand for single-asset SPVs amid growing liquidity and execution pressures As private markets firms navigate a more challenging fundraising and exit environment, limited partners (LPs) are demanding greater transparency, stronger governance rights, and more flexible SPV arrangements from fund managers. In fact, 86% of private markets professionals report increased LP requests for tailored SPV structures over the past 12 months, according to a new study by CSC, the leading provider of global business administration and compliance solutions. CSC¹ surveyed 410 senior private markets practitioners across private equity, private credit, real estate, and infrastructure to examine how investor demands are reshaping SPV structures, operating models, and execution requirements. The findings are detail
NetApp and Cisco Accelerate and Secure AI Innovation3.6.2026 14:00:00 CEST | Press release
New FlexPod solutions deliver proven performance, security, and unified management for AI NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Cisco (NASDAQ: CSCO) today announced that they have collaborated to offer new validated solutions for secure, scalable, and simplified AI. Expanding the proven success of FlexPod, the new solutions provide a simple, reliable path for enterprises to address the specific challenges AI workloads place on compute, network, and storage infrastructure. “As IT teams are tasked with delivering reliable, consistent performance across environments, AI workloads are placing increasing demands on their data infrastructure,” said Dallas Olson, Chief Commercial Officer at NetApp. “NetApp and Cisco’s longstanding partnership on FlexPod has already proven effective, saving customers up to 20 percent of their time in infrastructure management and maintenance. Now, we are applying our combined expertise to modern challenges to accelerate AI ad
New Evidence Offers Hope for Ketogenic Therapy in Treatment of Anorexia Nervosa3.6.2026 14:00:00 CEST | Press release
Peer-reviewed feasibility pilot trial reports reduced eating disorder and depressive symptoms in difficult-to-treat psychiatric condition A pilot study published today in Communications Medicine demonstrates the potential of a new approach to treating anorexia nervosa — a disorder for which effective treatments have been significantly limited. The research from UC San Diego School of Medicine reports that a ketogenic nutritional intervention — a high-fat, low-carbohydrate, moderate-protein diet — was feasible and safe for patients with weight-normalized and mildly underweight anorexia nervosa. The ketogenic intervention was well-tolerated by participants, with high adherence rates and no significant weight loss observed throughout the program. Furthermore, significant improvements were observed in eating disorder symptoms, with nearly 3 in 4 of study completers in the recovered range at study end, no longer meeting criteria for an anorexia nervosa diagnosis, and all completers experien
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom